Begins Coverage on OpGen (NASDAQ:OPGN) initiated coverage on shares of OpGen (NASDAQ:OPGNFree Report) in a research note issued to investors on Saturday morning. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Price Performance

Shares of OpGen stock opened at $0.40 on Friday. The firm’s fifty day simple moving average is $0.38 and its 200-day simple moving average is $0.41. The stock has a market capitalization of $4.00 million, a price-to-earnings ratio of -0.06 and a beta of -0.90. OpGen has a 12 month low of $0.17 and a 12 month high of $3.84.

OpGen (NASDAQ:OPGNGet Free Report) last announced its earnings results on Tuesday, November 14th. The medical research company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). The business had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.90 million. OpGen had a negative net margin of 852.18% and a negative return on equity of 316.30%. Analysts anticipate that OpGen will post -2.02 earnings per share for the current year.

Hedge Funds Weigh In On OpGen

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in OpGen by 39.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,877,597 shares of the medical research company’s stock valued at $537,000 after buying an additional 534,960 shares during the period. Dimensional Fund Advisors LP acquired a new position in OpGen in the 1st quarter valued at $49,000. Citadel Advisors LLC increased its stake in OpGen by 571.0% in the 3rd quarter. Citadel Advisors LLC now owns 100,773 shares of the medical research company’s stock valued at $29,000 after buying an additional 85,754 shares during the period. Finally, HRT Financial LP acquired a new position in OpGen in the 4th quarter valued at $26,000. 13.07% of the stock is owned by institutional investors and hedge funds.

About OpGen

(Get Free Report)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Featured Stories

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with's FREE daily email newsletter.